These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 29029708)

  • 1. Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants.
    Rosovsky R; Merli G
    Tech Vasc Interv Radiol; 2017 Sep; 20(3):141-151. PubMed ID: 29029708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Trujillo-Santos J; Di Micco P; Dentali F; Douketis J; Díaz-Peromingo JA; Núñez MJ; Cañas I; Mastroiacovo D; Saraiva de Sousa M; Monreal M;
    Thromb Haemost; 2017 Jan; 117(2):382-389. PubMed ID: 27786333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct oral anticoagulants and venous thromboembolism.
    Franchini M; Mannucci PM
    Eur Respir Rev; 2016 Sep; 25(141):295-302. PubMed ID: 27581829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulodexide for the extended treatment of venous thromboembolism.
    Walenga JM; Fareed J; Ramacciotti E
    Int Angiol; 2016 Dec; 35(6):531-533. PubMed ID: 27680735
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of cancer-associated venous thromboembolism - a case-based practical approach.
    Voigtlaender M; Langer F
    Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
    Finks SW; Trujillo TC; Dobesh PP
    Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
    Black SA; Cohen AT
    Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
    Haas S; Ageno W; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Dalsgaard Nielsen J; Kayani G; Zaghdoun A; Farjat AE; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK
    J Thromb Haemost; 2019 Oct; 17(10):1694-1706. PubMed ID: 31220403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Ageno W; Casella IB; Han CK; Raskob GE; Schellong S; Schulman S; Singer DE; Kimura K; Tang W; Desch M; Goldhaber SZ
    Thromb Haemost; 2017 Jan; 117(2):415-421. PubMed ID: 27853808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.
    Prescrire Int; 2015 Jun; 24(161):150. PubMed ID: 26436165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
    Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal duration of anticoagulation in patients with unprovoked venous thromboembolism: the impact of novel anticoagulants.
    Prandoni P; Milan M; Sarolo L; Zanon E; Bilora F
    Int Angiol; 2017 Oct; 36(5):395-401. PubMed ID: 27982558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
    Hirschl M; Kundi M
    Vasa; 2014 Sep; 43(5):353-64. PubMed ID: 25147012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New anticoagulants for treatment of venous thromboembolism.
    Franchini M; Mannucci PM
    Eur J Intern Med; 2012 Dec; 23(8):692-5. PubMed ID: 23095463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era.
    Toth PP
    Vasc Health Risk Manag; 2016; 12():23-34. PubMed ID: 26929637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.